{
  "id": 16394652,
  "title": "Climb Bio reports early data on budoprutug for kidney diseases",
  "url": "https://urgent.news/2026/10/24/climb-bio-reports-early-data-on-budoprutug-for-kidney-diseases",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-24T23:36:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/climb-bio-reports-early-data-on-budoprutug-for-kidney-diseases-93CH-4971000"
  },
  "original_language": "en",
  "account": "Wellesley Hills, Mass. - Climb Bio Inc., a company listed on NASDAQ as CLYM, recently shared early results from a study on budoprutug, an anti-CD19 monoclonal antibody. This trial focuses on two immune-related kidney conditions - primary membranous nephropathy and minimal change disease - and is currently in its Phase 2 PrisMN trial.\n\nThe Phase 2 trial is testing budoprutug with three different dosage levels: 200 mg, 600 mg, and 1,000 mg. After 12 weeks in the 200 mg group, the study revealed B-cell depletion and decreases in PLA2R antibody levels. A notable 5 out of the 13 patients in this cohort achieved immunologic remission. The reduction in PLA2R antibody levels was striking, dropping by 70% at Week 12. The reduction was even more significant for patients with a baseline PLA2R antibody level under 175 RU/mL, with a 80% reduction by Week 12.\n\nComparatively, the 600 mg dose group showed an even greater effect. At Week 4, budoprutug suppressed 98% of peripheral CD20+ B-cells, much higher than the 74% suppression seen in the 200 mg group at the same time point.\n\nIn terms of safety, budoprutug was generally well-tolerated across both cohorts through Week 12 for the 200 mg dose and Week 6 for the 600 mg dose. The most frequently reported side effects were mild to moderate, and there were no serious adverse events, discontinuations, or deaths reported. Enrollment is still ongoing for the 1,000 mg cohort.\n\nInterestingly, the company's population pharmacokinetics analysis revealed that patients with high proteinuria excrete budoprutug at least twice as fast as those without proteinuria. Additionally, a case study presented at the conference detailed a patient with a recurring condition known as minimal change disease who received 100 mg of budoprutug, leading to a three-year steroid-free remission. The company has stated that more data from the PrisMN Phase 2 study is expected in 2027. It's worth noting that primary membranous nephropathy impacts around 75,000 people in the United States, currently without any FDA-approved treatment options.",
  "summary": null,
  "key_points": [
    "Climb Bio shares early Phase 2 trial results for budoprutug in kidney diseases",
    "Budoprutug shows B-cell depletion and 70% PLA2R antibody reduction in 200 mg group",
    "600 mg dose suppresses 98% of peripheral CD20+ B-cells at Week 4"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}